Clinical-stage biotech company Gritstone has dosed the first participants in a Phase I clinical trial of its second-generation, self-amplifying mRNA (SAM) Covid-19 vaccine.

Named GRT-R910, the vaccine is expected to boost and expand first-generation Covid-19 vaccines’ immunogenicity in people aged 60 years and above.

The single-centre Phase I trial is being performed in alliance with The University of Manchester and Manchester University NHS Foundation Trust in the UK.

GRT-R910 utilises a SAM vector formulated with lipid nanoparticles to deliver antigens against both SARS-CoV-2 spike protein and highly conserved viral protein regions consisting of T cell epitopes.

The self-amplification, prolonged duration and extent of antigen generation with SAM vaccines could enable a decrease of vaccine doses or avoid repeat administrations, the company said.

Gritstone added that GRT-R910 may trigger robust, sustainable and wide immune responses against SARS-CoV-2 variants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gritstone co-founder, president and CEO Andrew Allen said: “Our SAM COVID vaccine is designed to drive robust CD8+ T cell responses, in addition to strong neutralising antibody responses, offering the promise of longer-lasting immunity, especially in more vulnerable populations.

“Additionally, since viral surface proteins like the spike protein are evolving and sometimes partially evading vaccine-induced immunity, we designed GRT-R910 to have broad therapeutic potential against a wide array of SARS-CoV-2 variants by also delivering highly conserved viral proteins that may be less prone to antigenic drift.”

Sponsored by Gritstone, the open-label, dose-escalation Phase I trial will initially enrol 20 participants.

It will evaluate GRT-R910’s ability to boost the immunogenicity of AstraZeneca‘s first-generation Covid-19 vaccine, AZD1222 (Vaxzevria), in healthy adults aged 60 years and above.

The trial will check the dose, safety, tolerability and immunogenicity of two GRT-R910 dose levels at a minimum of four months following the second administration of the initial vaccine.

Preliminary data from the Phase I trial are anticipated in the first quarter of next year.

In March 2021, the company began dosing in GRT-R910’s Phase I study supported by the US National Institute of Allergy and Infectious Diseases (NIAID).